Introduction of sacubitril/valsartan in primary care follow‐up of heart failure: a prospective observational study (THESEUS)

Abstract Aims Switch from angiotensin converting enzyme inhibitor treatment to sacubitril/valsartan (sac/val) is associated with benefit in heart failure with reduced ejection fraction (HFrEF). Reports on management of this switch are largely based on randomized controlled trials, retrospective anal...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Thomas Dieterle, Stefan Schaefer, Ina Meyer, Gabriele Ackermann, Kashan Ahmed, Roger Hullin
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Oxford University Press 2020-08-01
Edice:	ESC Heart Failure
Témata:	Heart failure Disease management Primary care
On-line přístup:	https://doi.org/10.1002/ehf2.12716
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!